No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
PTN Palatin Technologies
- 1.8220
- -0.1180-6.08%
Close Jun 14 16:00 ET
- 1.8400
- +0.0180+0.99%
Post 18:38 ET
29.40MMarket Cap-669P/E (TTM)
1.9461High1.7500Low107.77KVolume1.9200Open1.9400Pre Close196.84KTurnover0.68%Turnover RatioLossP/E (Static)16.14MShares5.650052wk High18.59P/B28.85MFloat Cap1.430052wk Low--Dividend TTM15.84MShs Float2687.5000Historical High--Div YieldTTM10.11%Amplitude1.4300Historical Low1.8260Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Sector Update: Health Care Stocks Ease Late Afternoon
Health care stocks were softer late Wednesday afternoon, with the NYSE Health Care Index decreasing 0.3% and the Health Care Select Sector SPDR Fund (XLV) down 0.1%. The iShares Biotechnology ETF (IBB
Palatin Technologies Starts Phase 2 of Obesity Treatment Study
Palatin Technologies (PTN) said Wednesday it has started a phase 2 clinical trial to assess the safety and efficacy of bremelanotide, a melanocortin 4 receptor agonist, administered alongside tirzepat
H.C. Wainwright Maintains Palatin Technologies(PTN.US) With Buy Rating, Maintains Target Price $17
H.C. Wainwright analyst Joseph Pantginis maintains $Palatin Technologies(PTN.US)$ with a buy rating, and maintains the target price at $17.According to TipRanks data, the analyst has a success rate of
Express News | Palatin Technologies: Additional Studies Under Assessment for Multiple Metabolic Conditions
Express News | Palatin Technologies Inc: Topline Data Expected by End of Calendar Year 2024
Express News | Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity
Comments
$Palatin Technologies(PTN.US$ Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity! Topline data expected by EOY 2024!
1
🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
11
2
The co-administration of bremelanotide with tirzepatide represents a novel therapeutic strategy for the treatment of obesity.
Palatin Technologies, Inc. (NYSE American: PTN), a pioneering biopharmaceutical company, has recently made a significant stride in the treatment of obesity by gaining FDA clearance for its Investigational New Drug (IND) application. This clearance allows Palatin to proceed with a Phase 2 clinical study e...
Palatin Technologies, Inc. (NYSE American: PTN), a pioneering biopharmaceutical company, has recently made a significant stride in the treatment of obesity by gaining FDA clearance for its Investigational New Drug (IND) application. This clearance allows Palatin to proceed with a Phase 2 clinical study e...
$Palatin Technologies(PTN.US$ Reuters· 1 min ago
Palatin Announces FDA Clearance of Ind Application for the Co-Administration of Bremelanotide With Tirzepatide (GLP-1) for the Treatment of Obesity
Palatin Announces FDA Clearance of Ind Application for the Co-Administration of Bremelanotide With Tirzepatide (GLP-1) for the Treatment of Obesity
1
$Palatin Technologies(PTN.US$
NEWS
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
NEWS
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg